Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (se deschide o fereastră nouă)

Abdelrazik N, Fouda M

Sursă‎: Hematology 2007;12(6):533-41.

Index‎: PubMed 17852440

DOI‎: 10.1080/10245330701521572

https://www.ncbi.nlm.nih.gov/pubmed/17852440 (se deschide o fereastră nouă)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (se deschide o fereastră nouă)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Sursă‎: Cancer 2012;118(3):848-55.

Index‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (se deschide o fereastră nouă)

Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (se deschide o fereastră nouă)

Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A

Sursă‎: Pediatr Hematol Oncol 2008;25(6):509-21.

Index‎: PubMed 18728970

DOI‎: 10.1080/08880010802235132

https://www.ncbi.nlm.nih.gov/pubmed/18728970 (se deschide o fereastră nouă)

Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (se deschide o fereastră nouă)

Durmaz O, Demirkaya M, Sevinir B

Sursă‎: Pediatr Hematol Oncol 2011;28(6):461-8.

Index‎: PubMed 21707225

DOI‎: 10.3109/08880018.2011.570857

https://www.ncbi.nlm.nih.gov/pubmed/21707225 (se deschide o fereastră nouă)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (se deschide o fereastră nouă)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Sursă‎: J Clin Oncol 2010;28(13):2239-45.

Index‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (se deschide o fereastră nouă)

Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (se deschide o fereastră nouă)

Hassan BA, Yusoff ZB

Sursă‎: Asian Pac J Cancer Prev 2011;12(6):1573-6.

Index‎: PubMed 22126501

https://www.ncbi.nlm.nih.gov/pubmed/22126501 (se deschide o fereastră nouă)

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (se deschide o fereastră nouă)

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group

Sursă‎: Curr Med Res Opin 2009;25(9):2109-20.

Index‎: PubMed 19601709

DOI‎: 10.1185/03007990903084164

https://www.ncbi.nlm.nih.gov/pubmed/19601709 (se deschide o fereastră nouă)

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (se deschide o fereastră nouă)

Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI

Sursă‎: J Support Oncol 2005;3(6 Suppl 4):10-1.

Index‎: PubMed 16355549

https://www.ncbi.nlm.nih.gov/pubmed/16355549 (se deschide o fereastră nouă)

The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (se deschide o fereastră nouă)

Hiradfar A, Banihosseinian M

Sursă‎: Iran J Ped Hematol Oncol 2014;4(4):151-9.

Index‎: PubMed 25598955

https://www.ncbi.nlm.nih.gov/pubmed/25598955 (se deschide o fereastră nouă)

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (se deschide o fereastră nouă)

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Sursă‎: Pediatr Blood Cancer 2009;53(1):7-12.

Index‎: PubMed 19229970

DOI‎: 10.1002/pbc.21953

https://www.ncbi.nlm.nih.gov/pubmed/19229970 (se deschide o fereastră nouă)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (se deschide o fereastră nouă)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Sursă‎: Cancer 2013;119(1):107-14.

Index‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (se deschide o fereastră nouă)

Erythropoietic growth factors for children with cancer: a systematic review of the literature. (se deschide o fereastră nouă)

Mystakidou K, Potamianou A, Tsilika E

Sursă‎: Curr Med Res Opin 2007;23(11):2841-7.

Index‎: PubMed 17910805

DOI‎: 10.1185/030079907x242601

https://www.ncbi.nlm.nih.gov/pubmed/17910805 (se deschide o fereastră nouă)

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (se deschide o fereastră nouă)

Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR

Sursă‎: J Clin Oncol 2006;24(22):3583-9.

Index‎: PubMed 16877725

DOI‎: 10.1200/JCO.2005.03.4371

https://www.ncbi.nlm.nih.gov/pubmed/16877725 (se deschide o fereastră nouă)

The role of recombinant erythropoietin in childhood cancer. (se deschide o fereastră nouă)

Shankar AG

Sursă‎: Oncologist 2008;13(2):157-66.

Index‎: PubMed 18305061

DOI‎: 10.1634/theoncologist.2007-0126

https://www.ncbi.nlm.nih.gov/pubmed/18305061 (se deschide o fereastră nouă)

Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (se deschide o fereastră nouă)

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, Piedra P, Saurez G, Verdecia M, Cabanas R

Sursă‎: MEDICC Rev 2010;12(3):27-31.

Index‎: PubMed 20697335

DOI‎: 10.37757/MR2010.V12.N3.7

https://www.ncbi.nlm.nih.gov/pubmed/20697335 (se deschide o fereastră nouă)

A single institutional experience: is epoetin alpha effective in anemic children with cancer? (se deschide o fereastră nouă)

Yilmaz D, Cetingül N, Kantar M, Oniz H, Kansoy S, Kavakli K

Sursă‎: Pediatr Hematol Oncol 2004;21(1):1-8.

Index‎: PubMed 14660300

https://www.ncbi.nlm.nih.gov/pubmed/14660300 (se deschide o fereastră nouă)

Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (se deschide o fereastră nouă)

Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, Wali Y

Sursă‎: Pediatr Hematol Oncol 2014;31(5):442-7.

Index‎: PubMed 24088186

DOI‎: 10.3109/08880018.2013.824527

https://www.ncbi.nlm.nih.gov/pubmed/24088186 (se deschide o fereastră nouă)

Early epoetin alfa treatment in children with solid tumors. (se deschide o fereastră nouă)

Zoubek A, Kronberger M

Sursă‎: Med Pediatr Oncol 2002;39(4):459-62.

Index‎: PubMed 12203664

DOI‎: 10.1002/mpo.10186

https://www.ncbi.nlm.nih.gov/pubmed/12203664 (se deschide o fereastră nouă)

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (se deschide o fereastră nouă)

Crary SE, Hall K, Buchanan GR.

Sursă‎: Pediatr Blood Cancer 2011;56(4):615-9.

Index‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

https://www.ncbi.nlm.nih.gov/pubmed/21298748 (se deschide o fereastră nouă)

Intravenous iron sucrose for children with iron deficiency anemia. (se deschide o fereastră nouă)

Kaneva K, Chow E, Rosenfield CG, Kelly MJ

Sursă‎: J Pediatr Hematol Oncol 2017;39(5):e259-62.

Index‎: PubMed 28562517

DOI‎: 10.1097/MPH.0000000000000879

https://www.ncbi.nlm.nih.gov/pubmed/28562517 (se deschide o fereastră nouă)

Advances in Pediatric Intravenous Iron Therapy. (se deschide o fereastră nouă)

Mantadakis E.

Sursă‎: Pediatr Blood Cancer 2016;63(1):11-6.

Index‎: PubMed 26376214

DOI‎: 10.1002/pbc.25752

https://www.ncbi.nlm.nih.gov/pubmed/26376214 (se deschide o fereastră nouă)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (se deschide o fereastră nouă)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Sursă‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Index‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (se deschide o fereastră nouă)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (se deschide o fereastră nouă)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Sursă‎: J Clin Oncol 2008;26(10):1619-25.

Index‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (se deschide o fereastră nouă)

Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (se deschide o fereastră nouă)

Plummer ES, Crary SE, McCavit TL, Buchanan GR

Sursă‎: Pediatr Blood Cancer 2013;60(11):1747-52.

Index‎: PubMed 23832487

DOI‎: 10.1002/pbc.24676

https://www.ncbi.nlm.nih.gov/pubmed/23832487 (se deschide o fereastră nouă)